LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Затворен

2.39 2.14

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.37

Максимум

2.43

Ключови измерители
By Trading Economics
Приходи	183K -27M
Служители	166
EBITDA	9.4M -27M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+192.89% upside

Дивиденти
By Dow Jones
Следващи печалби	24.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	60M 155M
Предишно отваряне	0.25
Предишно затваряне	2.39

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.23 / 1.45 Подкрепа & съпротива

Zentalis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.02.2026 г., 23:21 ч. UTC

Придобивния, сливания и поглъщания

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15.02.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Falls on Possible Position Adjustments -- Market Talk

15.02.2026 г., 23:06 ч. UTC

Печалби

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15.02.2026 г., 23:04 ч. UTC

Печалби

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15.02.2026 г., 23:04 ч. UTC

Печалби

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15.02.2026 г., 23:01 ч. UTC

Печалби

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15.02.2026 г., 23:01 ч. UTC

Печалби

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15.02.2026 г., 22:52 ч. UTC

Придобивния, сливания и поглъщания

Qube Shareholders to Receive A$5.20/Share in Cash

15.02.2026 г., 22:52 ч. UTC

Придобивния, сливания и поглъщания

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO Tania Archibald Speaking on a Call With Media

15.02.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15.02.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15.02.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15.02.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15.02.2026 г., 20:48 ч. UTC

Печалби

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15.02.2026 г., 20:47 ч. UTC

Печалби

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15.02.2026 г., 20:46 ч. UTC

Печалби

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15.02.2026 г., 20:45 ч. UTC

Печалби

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15.02.2026 г., 20:44 ч. UTC

Печалби

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15.02.2026 г., 20:44 ч. UTC

Печалби

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15.02.2026 г., 20:43 ч. UTC

Печалби

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15.02.2026 г., 20:42 ч. UTC

Печалби

BlueScope Net Debt A$2.2 Million at Dec. 31

15.02.2026 г., 20:42 ч. UTC

Печалби

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15.02.2026 г., 20:41 ч. UTC

Печалби

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15.02.2026 г., 20:40 ч. UTC

Печалби

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15.02.2026 г., 20:40 ч. UTC

Печалби

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15.02.2026 г., 20:39 ч. UTC

Печалби

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Сравнение с други в отрасъла

Ценова промяна

Zentalis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

192.89% нагоре

12-месечна прогноза

Среден 7 USD 192.89%

Висок 10 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Zentalis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Zentalis Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.23 / 1.45Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.